Benefits of high-dose N-acetylcysteine to exacerbation-prone patients with COPD

Area of Science:

• Pulmonology
• Pharmacology

Background:

• N-acetylcysteine (NAC) is investigated for its potential to reduce exacerbations in patients with Chronic Obstructive Pulmonary Disease (COPD).
• Optimal patient selection for NAC treatment in COPD remains unclear, necessitating further research into risk stratification.

Purpose of the Study:

• To compare the efficacy of high-dose N-acetylcysteine (NAC) in reducing COPD exacerbations between high-risk and low-risk Chinese patient cohorts.
• To determine if high-dose NAC offers differential benefits based on baseline exacerbation risk in COPD patients.

Main Methods:

• A randomized, placebo-controlled trial involving 120 stable COPD patients receiving either NAC 600 mg bid or placebo for one year.
• Patients were stratified into high-risk and low-risk groups based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria for subgroup analysis.
• Exacerbation frequency, time to first exacerbation, and the proportion of exacerbation-free patients were assessed over the 1-year study period.

Main Results:

• High-dose NAC significantly reduced exacerbation frequency in high-risk patients at 8 and 12 months (P = .019 and P = .04, respectively).
• Treatment with high-dose NAC prolonged the time to first exacerbation (P = .02) and increased the probability of being exacerbation-free at 1 year (51.3% vs 24.4%, P = .013) in high-risk individuals.
• No significant benefits of high-dose NAC on exacerbation rates were observed in low-risk COPD patients.

Conclusions:

• High-dose N-acetylcysteine (NAC) administered for one year demonstrates a significant benefit in reducing exacerbations for high-risk Chinese patients with COPD.
• The therapeutic effect of high-dose NAC is specific to high-risk populations, with no significant impact observed in low-risk COPD patients.